Valar Labs’ Vesta Bladder Risk Stratify Dx generates risk assessments for bladder cancer patients by analysing stained ...

Roche RHHBY announced that the FDA has approved a label expansion for Tecentriq (atezolizumab) and Tecentriq Hybreza ...

With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...

Securing Medicare coverage and launching our first TrueMRD Test are significant milestones for Veracyte and important steps in enabling access to our MRD testing platform,” said Marc Stapley, Veracyte ...

Natera said the Food and Drug Administration approved its Signatera CDx as a test for bladder cancer. The drug can be used as a companion diagnostic with adjuvant atezolizumab to treat muscle-invasive ...

Bladder cancer happens when cells in the bladder start to grow out of control. These cells can form a tumor and, over time, ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...